US › Healthcare

Inhibrx Biosciences, Inc. (INBX)

US · Healthcare · Biotechnology

$83.53+0.98%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-33.4M
Profit YoY
+22.8%
EPS
$-2.15
EPS estimate
$-1.20

EPS came in at -2.15 against a street estimate of -1.20 — a miss of 79.2%.

Key statistics

Market cap
$1.20B
Forward P/E
0.0
P/B
212.28
Book value
$-1.44
EPS (TTM)
$-8.39
52-week high
$155.29
52-week low
$20.55
50-day MA
$93.30
200-day MA
$83.79
Beta
3.43

Analyst view

with an average price target of $277.50.

Shareholding

Insiders
23.16%
Institutions
82.27%

Largest institutional holders

FundStake
Perceptive Advisors LLC9.83%
Viking Global Investors LP9.80%
Morgan Stanley - Brokerage Accounts8.61%
Sanofi7.89%
HighTower Advisors, LLC5.93%
BlackRock Inc5.45%
State Street Corp3.75%
Vanguard Capital Management, LLC3.32%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Inhibrx Biosciences, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.